A New Hope for Alzheimer’s Patients in Europe

In a move hailed as a potential step forward in the fight against Alzheimer’s disease, the European Commission has officially authorized the use of Leqembi, a treatment designed to slow cognitive decline in individuals experiencing early stages of the condition. This decision, announced Wednesday, follows a positive advice from the European Medicines Agency (EMA).

EMA’s Favorable Assessment Drives Approval

The authorization of Leqembi, developed jointly by Japanese pharmaceutical company EISAI and American manufacturer biogen, hinges on the EMA’s scientific evaluation. The agency concluded that the benefits of the drug outweigh the potential risks, paving the way for its introduction into the European market. The Commission stated in a press release that the decision was based on the EMA’s analysis.

Targeting Early Intervention: Who Can Benefit?

The EMA’s recommendation,issued in late 2024,specifically targets individuals wiht mild cognitive impairment or early-stage dementia due to Alzheimer’s disease. This focus on early intervention is crucial, as current research suggests that treatments are most effective when administered before significant brain damage has occurred. However, the EMA also emphasized the importance of risk stratification.

The green light is conditional, applying primarily to patients with a lower risk of cerebral hemorrhage. This typically includes individuals who possess “onyl one or no copy of the APOE4 gene,” a known genetic risk factor for Alzheimer’s. Genetic testing is therefore likely to become a standard procedure for determining patient eligibility.

Leqembi’s Global Journey and Safety Considerations

Leqembi received its initial approval in the United States in January 2023, extending hope to patients in the early phases of Alzheimer’s. It is also available in Japan and China. However,its rollout has not been without concerns. reports from the United States have linked the treatment to adverse effects, including fatalities and disabilities in a small number of patients. These incidents underscore the need for careful patient selection, rigorous monitoring, and obvious reporting of any adverse events.

According to the Alzheimer’s Association, more than 6 million Americans are living with Alzheimer’s. Globally, the number is estimated to be in the tens of millions, highlighting the urgent need for effective treatments.

The Ongoing Quest for an Alzheimer’s Breakthrough

Despite decades of intensive research, a definitive cure for Alzheimer’s disease remains elusive. Leqembi represents a significant, albeit incremental, advance in managing the disease’s progression. The approval of Leqembi offers a glimmer of hope for those in the early stages of Alzheimer’s, but it also serves as a reminder of the complexities of this devastating condition and the continued need for innovative research.

the profits of this drug were higher than the risks.

European Commission Press Release